36
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      OncoTargets and Therapy (submit here)

      This international, peer-reviewed Open Access journal by Dove Medical Press focuses on the pathological basis of cancers, potential targets for therapy and treatment protocols to improve the management of cancer patients. Publishing high-quality, original research on molecular aspects of cancer, including the molecular diagnosis, since 2008. Sign up for email alerts here. 50,877 Monthly downloads/views I 4.345 Impact Factor I 7.0 CiteScore I 0.81 Source Normalized Impact per Paper (SNIP) I 0.811 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Repression of PCGF1 Decreases the Proliferation of Glioblastoma Cells in Association with Inactivation of c-Myc Signaling Pathway

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Glioblastoma (GBM) is the most common primary brain tumor with a poor therapeutic outcome. Polycomb group factor 1 (PCGF1), a member of the PcG (Polycomb group) family, is highly expressed in the developing nervous system of mice. However, the function and the mechanism of PCGF1 in GBM proliferation still remain unclear.

          Methods

          Knockdown of PCGF1 was performed in U87 GBM cell by shRNA strategy via lentivirus vector. MTT assay, colony formation assays, and flow cytometry were used to measure the properties of cell proliferation and cell cycle distribution, respectively. GeneChip analysis was performed to identify the downstream effector molecules. Rescue assay was constructed to verify the screening results.

          Results

          We first found that knockdown of PCGF1 led to the inhibition of U87 cells proliferation and decreased colony formation ability. The data from GeneChip expression profiling and Ingenuity Pathway Analysis (IPA) indicated that many of the altered gene cells are associated with the cell proliferation control pathways. We have further confirmed the suppression of AKT/GSK3β/c-Myc/cyclinD1 expressions by Western blotting analysis. The over-expression of c-Myc could partly restore the attenuated proliferation ability caused by knockdown of PCGF1.

          Conclusion

          All the above evidences suggested that PCGF1 might be closely associated with tumorigenesis and progression of glioblastoma (GBM), in which process the oncoprotein c-Myc may participate. PCGF1 could thus be a potential therapeutic target for the treatment of glioblastoma (GBM).

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.

          Polycomb Group (PcG) proteins are transcriptional repressors that epigenetically modify chromatin and participate in the establishment and maintenance of cell fates. These proteins play important roles in both stem cell self-renewal and in cancer development. Our understanding of their mechanism of action has greatly advanced over the past 10 years, but many unanswered questions remain. In this review, we present the currently available experimental data that connect PcG protein function with some of the key processes which govern somatic stem cell activity. We also highlight recent studies suggesting that a delicate balance in PcG gene dosage is crucial for proper stem cell homeostasis and prevention of cancer stem cell development. Copyright 2010 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

            Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epidemiology of gliomas.

              Gliomas are the most common type of primary intracranial tumors. Some glioma subtypes cause significant mortality and morbidity that are disproportionate to their relatively rare incidence. A very small proportion of glioma cases can be attributed to inherited genetic disorders. Many potential risk factors for glioma have been studied to date, but few provide explanation for the number of brain tumors identified. The most significant of these factors includes increased risk due to exposure to ionizing radiation, and decreased risk with history of allergy or atopic disease. The potential effect of exposure to cellular phones has been studied extensively, but the results remain inconclusive. Recent genomic analyses, using the genome-wide association study (GWAS) design, have identified several inherited risk variants that are associated with increased glioma risk. The following chapter provides an overview of the current state of research in the epidemiology of intracranial glioma.
                Bookmark

                Author and article information

                Journal
                Onco Targets Ther
                Onco Targets Ther
                OTT
                ott
                OncoTargets and therapy
                Dove
                1178-6930
                09 January 2020
                2020
                : 13
                : 253-261
                Affiliations
                [1 ]Department of Thoracic Surgery, The Third Medical Center, Chinese People’s Liberation Army General Hospital , Beijing 100039, People’s Republic of China
                [2 ]Department of Radiation Medicine, School of Radiation Medicine and Protection, Medical College of Soochow University , Suzhou 215123, People’s Republic of China
                [3 ]Editorial Department, Logistic University of Chinese People’s Armed Police Force , Tianjin 300309, People’s Republic of China
                [4 ]Central Laboratory, Xi Qing Hospital , Tianjin 300380, People’s Republic of China
                [5 ]Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine , Tianjin 300050, People’s Republic of China
                Author notes
                Correspondence: Xuewei Chen; Rong Fan Email chenxuewei11@sina.com; prosperity_39@sina.cn
                [*]

                These authors contributed equally to this work

                Author information
                http://orcid.org/0000-0002-9861-5307
                http://orcid.org/0000-0001-6569-5630
                http://orcid.org/0000-0002-3388-0847
                Article
                234517
                10.2147/OTT.S234517
                6957096
                f97e556d-789c-4ae0-a15c-10e69c643c8d
                © 2020 Yan et al.

                This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

                History
                : 13 October 2019
                : 12 December 2019
                Page count
                Figures: 4, References: 51, Pages: 9
                Funding
                This work was supported by the National Natural Science Foundation of China, No. 81201757; BWS17J025, AWS16J004; and the Basic Research Projects of Logistic University of Chinese People’s Armed Police Force, No.WHJ201702.
                Categories
                Original Research

                Oncology & Radiotherapy
                glioblastoma,gbm,pcgf1,cell proliferation,polycomb group
                Oncology & Radiotherapy
                glioblastoma, gbm, pcgf1, cell proliferation, polycomb group

                Comments

                Comment on this article